Abu Abeid Subhi, Szold Amir, Gavert Nancy, Goldiner Ilana, Grynberg Elisheva, Peretz Hava, Konikoff Fred M
Tel-Aviv Sourasky Medical Center, Minerva Center for Cholesterol Gallstones and Lipid Metabolism in the Liver, Sackler Faculty of Medicine, Tel Aviv University, Israel.
Obes Surg. 2002 Jun;12(3):354-7. doi: 10.1381/096089202321087850.
Obesity and especially rapid weight loss following bariatric surgery are known risk factors for cholelithiasis. Since the risk may be high, prophylactic cholecystectomy has been advocated. Apolipoprotein (Apo) E, an important carrier protein in cholesterol metabolism and trafficking, is believed to play a role in gallstone pathogenesis. In particular, the Apo E4 allele has been suggested to be associated with cholesterol cholelithiasis. The aim of this study was to assess the incidence of postoperative cholelithiasis in our patient population and to determine a possible correlation with the Apo-E genotype.
134 morbidly obese patients undergoing gastric restrictive surgery [laparoscopic assisted gastric banding (LAGB) or silastic ring vertical gastroplasty (SRVG)] had abdominal ultrasound before and 6 to 12 months after operation, to determine the presence of gallstones. None of the patients enrolled in the study had gallstones before surgery. They did not have a prophylactic cholecystectomy or receive bile salt treatment. Apo-E genotypes were determined by Polymerase Chain Reaction restriction enzyme analysis.
10 patients (7.5%) developed postoperative cholelithiasis. The incidence of cholelithiasis in each ApoE genotype was: E2/E3--1/20 (5%), E3/E3--3/91 (3%), E3/E4--6/21 (29%), and E4/E4--0/2. ApoE allele frequencies in the study population were identical to those of a healthy control population. The mean BMI dropped from 43.6 to 29.4 kg/m2.
The occurrence of postoperative gallstones was low in our population. However, in subjects with the Apo-E3/E4 genotype, the incidence is of practical significance. These data suggest that Apo-E genotyping may be useful in selecting patients for gallstone prevention (surgical or medical) when undergoing bariatric surgery. Further testing in larger patient populations may be able to give more definite guidelines in the future.
肥胖尤其是减肥手术后的快速体重减轻是已知的胆结石危险因素。由于风险可能很高,因此有人主张进行预防性胆囊切除术。载脂蛋白(Apo)E是胆固醇代谢和运输中的一种重要载体蛋白,被认为在胆结石发病机制中起作用。特别是,有人提出Apo E4等位基因与胆固醇性胆结石有关。本研究的目的是评估我们患者群体中术后胆结石的发生率,并确定其与Apo-E基因型的可能相关性。
134例接受胃限制性手术[腹腔镜辅助胃束带术(LAGB)或硅胶环垂直胃成形术(SRVG)]的病态肥胖患者在术前及术后6至12个月接受腹部超声检查,以确定是否存在胆结石。纳入研究的患者术前均无胆结石。他们未接受预防性胆囊切除术或胆汁盐治疗。通过聚合酶链反应限制性酶分析确定Apo-E基因型。
10例患者(7.5%)发生术后胆结石。每种ApoE基因型的胆结石发生率分别为:E2/E3--1/20(5%),E3/E3--3/91(3%),E3/E4--6/21(29%),E4/E4--0/2。研究人群中的ApoE等位基因频率与健康对照人群相同。平均体重指数从43.6降至29.4kg/m²。
我们的患者群体中术后胆结石的发生率较低。然而,对于Apo-E3/E4基因型的患者,该发生率具有实际意义。这些数据表明,Apo-E基因分型可能有助于在减肥手术中选择胆结石预防(手术或药物)患者。未来在更大患者群体中的进一步检测可能能够给出更明确的指导方针。